Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 146 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Selective serotonin reuptake inhibitor Clear all
Terminated Phase 2 Interventional Results available

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

NCT01103180
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Combined Treatment for Alcohol-Dependent Individuals With PTSD

NCT00262223
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Alcohol Abuse, Substance-Related Disorders
Interventions
Seeking Safety, Sertraline, Pill placebo
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

NCT01811147
View directory record Official record
Conditions
Bipolar Disorder, Major Depression
Interventions
Selective Serotonin Reuptake Inhibitor (SSRI)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
15 Years to 30 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 3, 2026, 7:33 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Partners in Caring for Anxious Youth

NCT04598230
View directory record Official record
Conditions
Anxiety, Separation, Anxiety, Generalized, Anxiety, Social
Interventions
Cognitive Behavioral Therapy (CBT), Combination therapy (COMB)
Behavioral · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
7 Years to 17 Years
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Results available

Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression

NCT00824044
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Escitalopram
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 3, 2026, 7:33 PM EDT
Terminated Phase 3 Interventional Results available

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

NCT01040208
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Depression
Interventions
flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs, placebo 2 tablets qhs
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
42
States / cities
Costa Mesa, California • Fresno, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01153347
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
79
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 3, 2026, 7:33 PM EDT
Completed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials, Relapse Study

NCT04933630
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

NCT02134808
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine, Placebo
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 4 Interventional

Predicting Treatment Response in Patients With OCD

NCT03993535
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
selective serotonin reuptake inhibitor
Drug
Lead sponsor
University of Sao Paulo
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 3, 2026, 7:33 PM EDT
Recruiting Phase 2 Interventional

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

NCT06633016
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ABX-002, Placebo
Drug · Other
Lead sponsor
Autobahn Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Citalopram in Irritable Bowel Syndrome

NCT00477165
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Citalopram, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 3, 2026, 7:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

SSRI Effects on Semen Parameters in Men

NCT00385762
View directory record Official record
Conditions
Healthy
Interventions
paroxetine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 3, 2026, 7:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

NCT04856124
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Intranasal esketamine
Drug
Lead sponsor
Psych Atlanta
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

NCT01045083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, escitalopram, methylphenidate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 3, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

NCT01299415
View directory record Official record
Conditions
Solid Tumors
Interventions
Vadimezan™
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
4
States / cities
Indianapolis, Indiana • Minneapolis, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

NCT01674361
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Bitopertin, Placebo, SSRI
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 3, 2026, 7:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of Depression on Thermoregulation

NCT06805851
View directory record Official record
Conditions
Depression, Selective Serotonin Reuptake Inhibitor
Interventions
Not listed
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 40 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

Exercise Plus Duloxetine for Knee Osteoarthritis

NCT04111627
View directory record Official record
Conditions
Knee Osteoarthritis, Depression
Interventions
Aerobic exercise, Duloxetine
Behavioral · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 3, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

NCT01187407
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chino, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 3, 2026, 7:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic

NCT02855580
View directory record Official record
Conditions
Obsessive Compulsive Disorder, Major Depressive Disorder, Anxiety
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 20 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 3, 2026, 7:33 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression

NCT01579942
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 3, 2026, 7:33 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 3, 2026, 7:33 PM EDT